MedTrace Logo

Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma

NCT05918185 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2026-02-03

No results posted yet for this study

Summary

This study evaluates the association between a comprehensive geriatric assessment and laboratory biomarkers with the side effects of chemotherapy in older patients with multiple myeloma (MM). The comprehensive geriatric assessment is a tool that can help to determine how fit a patient is. It is composed of a series of questions and tests designed for older people to evaluate their physical function, mental status, mental health, nutritional status, social support, level of social activity, and the presence of other medical problems. In addition to geriatric assessment domains, laboratory biomarkers may provide information on physiologic dysfunction as a measure for evaluation of frailty in the cancer setting. This study will help researchers in the future by predicting which patients will have more side effects with chemotherapy based on their comprehensive geriatric assessment and laboratory biomarkers, which will allow adjustments to treatment in older adult patients with MM.

Conditions

  • Plasma Cell Myeloma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Comprehensive Geriatric Assessment

Undergo cGA

OTHER

Electronic Health Record Review

Medical records are reviewed

OTHER

Survey Administration

Complete surveys

Sponsors & Collaborators

Principal Investigators

  • Shaji K. Kumar, MD · Mayo Clinic in Rochester

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2025-08-30
Completion
2025-08-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05918185 on ClinicalTrials.gov